Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | CCR8 | P51685 | 12/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL578981 | 0.81 | SLC1A3 (0.49) | NAMPTIDO1ALDH1A1KMT2AMEN1 | |
| SCHEMBL578845 | 0.78 | PIK3CD (0.43) | NAMPTPIK3CDPIK3CGALDH1A1KMT2A | |
| SCHEMBL17203731 | 0.75 | CA2 (0.53) | ALDH1A1 | |
| SCHEMBL8513847 | 0.74 | ALDH1A1 (0.55) | NAMPTPIK3CDPIK3CBPIK3CGIDO1 | |
| SCHEMBL586613 | 0.74 | ALDH1A1 (0.55) | NAMPTPIK3CDPIK3CBPIK3CGIDO1 | |
| SCHEMBL3721269 | 0.71 | FEN1 (0.39) | PIK3CDPIK3CGALDH1A1KMT2AMEN1 | |
| SCHEMBL8533219 | 0.71 | FEN1 (0.39) | PIK3CDPIK3CGALDH1A1KMT2AMEN1 | |
| SCHEMBL578990 | 0.70 | SLC1A3 (0.31) | — | |
| SCHEMBL20019662 | 0.68 | SMN1; SMN2 (0.46) | PIK3CDPIK3CGALDH1A1 | |
| SCHEMBL9833963 | 0.67 | ALDH1A1 (0.49) | NAMPTCCR8ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735414-B2 | Indole derivatives and methods for antiviral treatment | PTC THERAPEUTICS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20120184574-A1 | INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT | PTC THERAPEUTICS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| EP-2417122-A1 | INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT | PTC Therapeutics, Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010117932-A1 | INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184574-A1 | INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT | IDO1, IRF3, MAVS | NAMPT 865/4885PIK3CD 2508/4885PIK3CB 1933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.